by Maria Zannes | Sep 1, 2022 | Press Releases
SEPTEMBER 1, 2022(SAN ANTONIO, TX) bioAffinity Technologies, Inc., a cancer diagnostics company that develops non-invasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that...
by Maria Zannes | Mar 24, 2022 | Events
Maria Zannes, President & CEO, will discuss keys to a start-up company’s success as part of San Antonio BioMed’s BioFest Invest event on March 30, 2022. Zannes will be on a panel of CEOs presenting to investors, companies and business leaders at the annual spring...
by Maria Zannes | Dec 6, 2021 | Events
bioAffinity discoveries lead to novel approach that kills cancer cells without harm to normal cells by using siRNAs to selectively target multiple cancers DECEMBER 6, 2021 (SAN ANTONIO, TX) bioAffinity Vice President of Research David Elzi, Ph.D., will discuss how...
by Maria Zannes | Oct 14, 2021 | Press Releases
Reveles leads CyPath® Lung, a non-invasive and highly accurate test for lung cancer, as it enters the market OCTOBER 14, 2021 (SAN ANTONIO, TX) bioAffinity Technologies today announced that Xavier T. Reveles, MS, CG, has been promoted to Vice President of Operations....
by Maria Zannes | Sep 29, 2021 | Events
Vice President of Research David Elzi, PhD, will present groundbreaking research leading to bioAffinity’s discovery of how silencing two cell receptors results in cancer cell toxicity, while normal cells are unaffected. His presentation at the American Society of...
